MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
0.8972
+0.0072 (0.81%)
Apr 15, 2025, 4:00 PM EDT - Market closed
MIRA Pharmaceuticals Employees
MIRA Pharmaceuticals had 3 employees as of December 31, 2023.
Employees
3
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,617,553
Market Cap
15.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | - | - |
MIRA News
- 14 days ago - MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain - Accesswire
- 22 days ago - MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development - Accesswire
- 4 weeks ago - MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain - Accesswire
- 6 weeks ago - MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain - Accesswire
- 4 months ago - MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - Accesswire
- 4 months ago - MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - Accesswire
- 5 months ago - MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site - Accesswire
- 6 months ago - MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - Accesswire